Islatravir (MK-8591)
(Synonyms: 2'-脱氧-4'-C-乙炔基-2-氟腺苷,MK-8591) 目录号 : GC32306A nucleoside reverse transcriptase inhibitor
Cas No.:865363-93-5
Sample solution is provided at 25 µL, 10mM.
EFdA is a nucleoside reverse transcriptase inhibitor (NRTI).1 It inhibits HIV-1 reverse transcriptase via multiple mechanisms. EFdA inhibits replication of the HIV-1 strain HIV-1 IIIb, the laboratory isolate HIV NL4-3, and the clinical isolate HIV-2 EHO in MT-4 cells (EC50s = 73, 50, and 98 pM, respectively).2 It is also active against drug-resistant HIV with EC50 values ranging from 0.23 to 23 nM in a multinuclear activation of a galactosidase indicator (MAGI) assay.3 EFdA (1 and 10 mg/kg per day) prevents infection with HIV JR-CSF in humanized mice.4
1.Michailidis, E., Huber, A.D., Ryan, E.M., et al.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsJ. Biol. Chem.289(35)24533-24548(2014) 2.Markowitz, M., and Sarafianos, S.G.4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: A novel HIV-1 reverse transcriptase translocation inhibitorCurr. Opin. HIV AIDS13(4)294-299(2018) 3.Kawamoto, A., Kodama, E., Sarafianos, S.G., et al.2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variantsInt. J. Biochem. Cell Biol.40(11)2410-2420(2008) 4.Stoddart, C.A., Galkina, S.A., Joshi, P., et al.Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaqueAntimicrob. Agents Chemother.59(7)4190-4198(2015)
Cas No. | 865363-93-5 | SDF | |
别名 | 2'-脱氧-4'-C-乙炔基-2-氟腺苷,MK-8591 | ||
Canonical SMILES | OC[C@]1(C#C)[C@H](C[C@H](N2C=NC3=C2N=C(F)N=C3N)O1)O | ||
分子式 | C12H12FN5O3 | 分子量 | 293.25 |
溶解度 | DMSO: 20.83 mg/mL (71.03 mM; ultrasonic and adjust pH to 3 with HCl); Water: 3.57 mg/mL (12.17 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.4101 mL | 17.0503 mL | 34.1006 mL |
5 mM | 0.682 mL | 3.4101 mL | 6.8201 mL |
10 mM | 0.341 mL | 1.705 mL | 3.4101 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet